Assessing the Magnitude of Anisometropia in Patients Wearing Misight 1 Day Contact Lens
- Conditions
- MyopiaAnisometropia
- Registration Number
- NCT06744478
- Lead Sponsor
- Buddhist Tzu Chi General Hospital
- Brief Summary
The effectiveness of Misight 1 Day Contact Lens in retarding anisometropic progression has not been investigated before. This study is aimed to elucidate the efficacy of Misight 1 Day Contact Lens for anisometropia control.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 50
- 8-23 years old children diagnosed with anisometropia and are willing to accept MiSight® 1 Day contact lens wearing treatment.
- No congenital eye diseases or eye diseases such as strabismus and amblyopia.
- Those who have been stated to be willing to participate in the program for at least 24 months and accept various evaluations.
- Ocular surface disease( dry eye, keratoconus..)
- Allergy to contact lens
- Received eye surgery before
- The cornea is infected (bacterial, fungal or viral infection).
- Strabismus
- Premature birth
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of the visual acuity in myopic children with different Misight 1 Day Contact Lens From the date of starting treatment, the visual acuity was measured 1 week, 1month and every 3 months up to 24 months. The investigators measure the visual acuity of myopic children with different Misight 1 Day Contact Lens.
- Secondary Outcome Measures
Name Time Method Changes of axial length in myopic children with different Misight 1 Day Contact Lens From the date of starting treatment, the axial length was measured, then repeat measure were performed every 6 months up to 24 months The investigators measure the axial length(mm) of eyeball of myopic children with different diopter of Misight 1 Day Contact Lens.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Shang-Yen WU
🇨🇳Hualien City, Taiwan